secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001828185-24-000034
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio Q1 net loss $15.5M ($0.40/sh); cash $130M; VTP-1000 IND cleared for celiac trial
--------------------------------------------------------------------------------

- Net loss attributable to shareholders of $15.5M vs $18.2M in Q1 2023; revenue nil (vs $0.5M).
- Cash, cash equivalents and restricted cash of $130.0M as of March 31, 2024; cash runway into Q4 2025.
- R&D expenses $11.1M (up from $9.8M), G&A $6.0M (down from $12.1M).
- FDA IND clearance received for VTP-1000 Phase 1 trial in celiac disease; first patient dosing expected Q3 2024.
- Appointed Dr. Leon Hooftman as CMO, effective June 3, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000034/0001828185-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818524000034/brns-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001828185-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer